Health economics builds evidence for the cost-effectiveness and cost-benefit of integrating genomic medicine into the Australian healthcare system with the aim of informing state, territory and Federal Government policy.
We work closely with families, clinicians and the Australian public.
We apply preference-elicitation and decision modelling methods to inform the optimal and cost-effective implementation of genomic medicine.
Our work has quantified:
- How genetic conditions affect the quality-of-life of children and parents read more.
- The value of genomic medicine from the perspective of the Australian public across rare diseases and for children who are critically ill or experience complex neurodevelopmental conditions.
- The value of genomic medicine from the perspective of parents and adult patients with lived experience of genetic conditions read more.
- The cost-effectiveness of genomic medicine for Australian healthcare, including childhood mitochondrial disorders.
While our work continues to grow, enabling a broader understanding of the health economic implications of genetic conditions and genomic medicine in Australia, it ensures that families experiencing genetic conditions are not disadvantaged in resource allocation decisions and policy decisions are made with the objective of offering high-value care.
Australian Genomics supports the efforts of the Economics of Genomics and Precision Medicine working group within the international Health Economics Association to build capacity in the economics of genomic medicine globally.
Click the links below to access related surveys and other resources:
- Quantifying clinical utility and associated resource use following genomic testing for mitochondrial disorders and developmental epileptic encephalopathy
- Eliciting the value of genomic testing using a dynamic triple-bounded dichotomous choice and a payment card contingent valuation methods
- Eliciting the value of genomic testing using a discrete choice experiment method